Sox17-flox Mouse
Common Name
Sox17-flox
제품 ID
S-CKO-05182
Backgroud
C57BL/6JCya
품종 계통계통 ID
CKOCMP-20671-Sox17-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Sox17-flox Mouse (카탈로그 번호 S-CKO-05182)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Sox17-flox
품종 계통계통 ID
CKOCMP-20671-Sox17-B6J-VA
유전자명
제품 ID
S-CKO-05182
유전자 별칭
--
배경
C57BL/6JCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 1
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000027035
NCBI 전사체 ID
NM_011441
타겟 영역
Exon 5
유효 영역 크기
~2.7 kb
유전자 연구 개요
SOX17, SRY-box transcription factor 17, is a crucial transcription factor. It directs the specification and development of the primitive endoderm, primitive germ cells, and definitive endoderm, and is involved in the cardiovascular system and several endoderm-derived organs. It participates in pathways like Wnt/β-catenin and Notch signaling during development [5,7].
In cancer, in vitro-engineered colon cancer organoids with Apc-null, KrasG12D and Trp53-null (AKP) mutations showed strong up-regulation of SOX17 in vivo. SOX17 loss did not impact AKP organoid propagation in vitro but significantly reduced AKP tumour persistence in vivo. SOX17-null tumours had IFNγ-producing effector-like CD8+ T cell infiltrates, unlike the immune-suppressive microenvironment in wild-type counterparts. SOX17 suppresses tumour cells' ability to sense and respond to IFNγ, and engages a fetal intestinal programme to drive differentiation away from LGR5+ tumour cells, producing immune-evasive LGR5-tumour cells with lower MHC-I expression, enabling immune evasion in early colorectal adenomas and cancers [1].
In pulmonary hypertension, SOX17 expression was downregulated in patients' lungs and pulmonary endothelial cells. Tie2Cre-mediated Sox17 knockdown and EC-specific Sox17 deletion in mice induced spontaneous mild pulmonary hypertension, and loss of endothelial Sox17 exacerbated hypoxia-induced pulmonary hypertension. SOX17 deficiency led to endothelial dysfunctions, and E2F1 signaling mediated these effects, which could be attenuated by E2F1 inhibitor [2]. Also, Sox17 expression was reduced in PAH tissues. Chronic hypoxic pulmonary hypertension was exacerbated in Sox17EC-/-mice and attenuated in Sox17Tg mice. SOX17 promoted oxidative phosphorylation and mitochondrial function in pulmonary artery endothelial cells, in part via inhibition of HIF2α. 16α-hydroxyestrone (16αOHE) mediated PAH development via down-regulation of SOX17 [3]. Common PAH risk variants upstream of the SOX17 promoter reduced endothelial SOX17 expression through differential binding of HOXA5 and ROR-α, resulting in disturbed endothelial cell function and PAH [4]. Endothelial knockdown of SOX17 accelerated, while overexpression attenuated, SU5416/hypoxia-induced PH in mice. SOX17-associated exosomes blocked HPAECs' proliferation, apoptosis, and inflammation, preventing pulmonary arterial remodeling and PH [6].
In conclusion, SOX17 is vital for embryonic development and tissue homeostasis. Gene-knockout and conditional-knockout mouse models have revealed its role in promoting immune evasion in early colorectal cancers and maintaining endothelial function to prevent pulmonary hypertension. Understanding SOX17's functions provides insights into disease mechanisms and potential therapeutic targets for these diseases.
References:
1. Goto, Norihiro, Westcott, Peter M K, Goto, Saori, Agudo, Judith, Yilmaz, Ömer H. 2024. SOX17 enables immune evasion of early colorectal adenomas and cancers. In Nature, 627, 636-645. doi:10.1038/s41586-024-07135-3. https://pubmed.ncbi.nlm.nih.gov/38418875/
2. Yi, Dan, Liu, Bin, Ding, Hongxu, Fallon, Michael B, Dai, Zhiyu. 2023. E2F1 Mediates SOX17 Deficiency-Induced Pulmonary Hypertension. In Hypertension (Dallas, Tex. : 1979), 80, 2357-2371. doi:10.1161/HYPERTENSIONAHA.123.21241. https://pubmed.ncbi.nlm.nih.gov/37737027/
3. Sangam, Shreya, Sun, Xutong, Schwantes-An, Tae-Hwi, Black, Stephen M, Desai, Ankit A. . SOX17 Deficiency Mediates Pulmonary Hypertension: At the Crossroads of Sex, Metabolism, and Genetics. In American journal of respiratory and critical care medicine, 207, 1055-1069. doi:10.1164/rccm.202203-0450OC. https://pubmed.ncbi.nlm.nih.gov/36913491/
4. Walters, Rachel, Vasilaki, Eleni, Aman, Jurjan, Zhao, Lan, Rhodes, Christopher J. 2023. SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. In Circulation, 147, 1606-1621. doi:10.1161/CIRCULATIONAHA.122.061940. https://pubmed.ncbi.nlm.nih.gov/37066790/
5. Tan, Daisylyn Senna, Holzner, Markus, Weng, Mingxi, Srivastava, Yogesh, Jauch, Ralf. 2019. SOX17 in cellular reprogramming and cancer. In Seminars in cancer biology, 67, 65-73. doi:10.1016/j.semcancer.2019.08.008. https://pubmed.ncbi.nlm.nih.gov/31419525/
6. Zou, Xiaozhou, Liu, Ting, Huang, Zhongjie, Zhang, Yiwen, Huang, Ping. 2023. SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome-Mediated Autocrine Manner. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10, e2206139. doi:10.1002/advs.202206139. https://pubmed.ncbi.nlm.nih.gov/36919784/
7. Zhu, Na, Welch, Carrie L, Wang, Jiayao, Shen, Yufeng, Chung, Wendy K. 2018. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. In Genome medicine, 10, 56. doi:10.1186/s13073-018-0566-x. https://pubmed.ncbi.nlm.nih.gov/30029678/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
